期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 64, 期 4, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01872-19
关键词
ESBL-producing Klebsiella pneumoniae; XDR Pseudomonas aeruginosa; cefiderocol; chronic osteomyelitis; pediatric
资金
- NIH/NIAID [K08 AI135093, R01 AI134637, R21 AI143229, K24 AI121296]
- UTHealth Presidential Award
- University of Texas System STARS Award
- Texas Medical Center Health Policy Institute Funding Program
- Merck, Inc.
- MeMed Diagnostics
- Merck
- Entasis Therapeutics pharmaceuticals
- Entasis Therapeutics
We report a 15 year-old Nigerian adolescent male with chronic osteomyelitis caused by an extensively drug-resistant (XDR) Pseudomonas aeruginosa strain of sequence type 773 (ST773) carrying bla(NDM-1) and an extended spectrum beta-lactamase (ESBL)-producing Klebsiella pneurnoniae strain. The patient developed neurological side effects in the form of circumoral paresthesia with polymyxin B and asymptomatic elevation of transaminases with aztreonam (used in combination with ceftazidime-avibactam). Cefiderocol treatment for 14 weeks plus bone implantation resulted in apparent cure and avoided amputation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据